Company News & Announcements

November 16, 2009

XANODYNE ANNOUNCES FDA APPROVAL OF LYSTEDA™ (tranexamic acid) FOR TREATMENT OF WOMEN WITH HEAVY MENSTRUAL BLEEDING

November 12, 2009

XANODYNE EXPANDS U.S. SALES FORCE AND LAUNCHES ZIPSOR™ (DICLOFENAC POTASSIUM) LIQUID FILLED CAPSULES

October 29, 2009

XANODYNE RAISES $50 MILLION IN EQUITY FINANCING

[ Corporate Governance ]

Xanodyne

Welcome to Xanodyne

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. We market a portfolio of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.

Recently Approved: Zipsor™ for the treatment of mild to moderate acute pain in adults was approved by the FDA on June 16, 2009. Lysteda™ was approved following a Priority Review by the FDA for the treatment of cyclic heavy menstrual bleeding on November 13, 2009.

We are Developing: XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S.

Product Highlights

Oramorph SR

Oramorph is a sustained release morphine tablet indicated for pain in patients who require opioid analgesia for more than a few days... [MORE]